Open | $5.090 |
Close | $5.170 |
Volume / Avg. | 1.829M / 1.460M |
Day Range | 4.200 - 5.400 |
52 Wk Range | 0.940 - 6.060 |
Market Cap | $233.215M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 79 |
Short Interest | 2.74% |
Days to Cover | 4.2 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Cardiff Oncology (NASDAQ: CRDF) through any online brokerage.
Other companies in Cardiff Oncology’s space includes: Innate Pharma (NASDAQ:IPHA), FibroGen (NASDAQ:FGEN), Inovio Pharmaceuticals (NASDAQ:INO), Gritstone Bio (NASDAQ:GRTS) and Mesoblast (NASDAQ:MESO).
The latest price target for Cardiff Oncology (NASDAQ: CRDF) was reported by HC Wainwright & Co. on Wednesday, March 6, 2024. The analyst firm set a price target for 14.00 expecting CRDF to rise to within 12 months (a possible 168.20% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Cardiff Oncology (NASDAQ: CRDF) is $5.22 last updated March 18, 2024 at 6:55 PM EDT.
There are no upcoming dividends for Cardiff Oncology.
Cardiff Oncology’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for Cardiff Oncology.
Cardiff Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.